{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086035","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.861283+00:00","generated_at":"2026-06-12T18:34:19.791881+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics gets UK authorization to start Phase 1 trial of ENTR-601-44 for Duchenne","bullets":["UK MHRA and REC authorized Phase 1 CTIMP for ENTR-601-44 in healthy volunteers for exon 44 skipping Duchenne.","Phase 1 will enroll ~40 participants; primary endpoint safety, plus tolerability, PK, and exon skipping in muscle.","First participant expected to be dosed September 2023; data anticipated in second half of 2024.","Cash runway extended through end of 2025, supporting Duchenne franchise and broader intracellular therapeutics.","ENTR-601-44 is lead Duchenne product candidate for patients amenable to exon 44 skipping."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086035","json":"https://secwatch.observer/filing/0001104659-23-086035.json","markdown":"https://secwatch.observer/filing/0001104659-23-086035.md","text":"https://secwatch.observer/filing/0001104659-23-086035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/0001104659-23-086035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923086035/tm2322453d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:34:19.791881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}